<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133561</url>
  </required_header>
  <id_info>
    <org_study_id>VHafez 2010</org_study_id>
    <nct_id>NCT01133561</nct_id>
  </id_info>
  <brief_title>Pioglitazone in Psoriasis- A Clinical and Molecular Study.</brief_title>
  <official_title>The CLINICAL And MOLECULAR EFFECTS Of An INSULIN SENSITIZING DRUG: 'PIOGLITAZONE'On PSORIASIS TREATMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in
      terms of improvement of both skin and systemic manifestations of psoriasis.

      The investigators assume that pioglitazone (one of thiazolidinediones readily available in
      Egypt), can regulate keratinocytes' disordered proliferation observed in psoriasis, in
      addition to improving the insulin resistance in peripheral tissues observed in many psoriatic
      patients and causing metabolic syndrome. This will allow to give a safer therapy than the
      available ones for psoriasis and to treat the patient in a more global perspective.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success detected as clinical improvement of skin condition</measure>
    <time_frame>10 weeks</time_frame>
    <description>PASI improvement by at least 50% from baseline before treatment(Psoriasis Area and Severity Index)= PASI-50</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting serum insulin reduction from baseline before treatment</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein titre reduction from baseline value before treatment</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>actozone A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 30 mg tablets daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>actozone B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>actozone A</intervention_name>
    <description>pioglitazone 30 mg tablet , once daily dose for 10 weeks</description>
    <arm_group_label>actozone A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>actozone B</intervention_name>
    <description>one tablet of vehicle without active ingredient pioglitazone</description>
    <arm_group_label>actozone B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and less than 65 years.

          -  Plaque psoriasis vulgaris ≥ 10% (apart from palmoplantar psoriasis which will be
             included).

        Exclusion Criteria:

          -  Age less than 18 years and more than 65 years

          -  Mild psoriasis less than 10% body surface area

          -  Erythrodermic or pustular psoriasis

          -  Liver disease, cardiac disease (suspected from history or ECG), or any other major
             medical disorder detected by history.

          -  Pregnant and lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manal AW Bosseila, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University-Dermatology department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona RE Abdel Halim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo university- Dermatology department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed I Sheta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo university- Internal medicine department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olfat G Shaker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University- Biochemistry department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology department of cairo university faculty of medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>February 22, 2011</last_update_submitted>
  <last_update_submitted_qc>February 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vanessa Galal Hafez/ Assistant lecturer of Dermatology</name_title>
    <organization>Dermatology department, Faculty of medicine, Cairo university</organization>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>pioglitazone</keyword>
  <keyword>randomized control trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

